Clinical Trial Update: Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection [Phase 4]

View source ↗

Summary

A Phase 4 trial to evaluate the efficacy of two products, 2LEBV and 2LXFS, on asthenia in patients with Epstein-Barr virus infection, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• 2LEBV
• 2LXFS

Snippet

Sponsor: Labo'Life | Conditions: EBV Infection | Phase 4 | Status: RECRUITING